# Qilu Pharmaceutical Co., Ltd.: Phase 3 study in Extrapulmonary Neuroendocrine Carcinoma (270 participants)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma |
| NCT ID | NCT07894211 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Extrapulmonary Neuroendocrine Carcinoma |
| Intervention types | drug |
| Target enrollment | 270 |
| Posted | 2026-10-26 |
| Planned start | 2026-10-26 |
| Event | Newly registered study |
| Event date | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 270 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07894211). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.